Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Non-Current Debt (2016 - 2025)

Apyx Medical (APYX) has disclosed Non-Current Debt for 13 consecutive years, with $34.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt rose 2.82% year-over-year to $34.8 million, compared with a TTM value of $34.8 million through Dec 2025, up 2.82%, and an annual FY2025 reading of $34.8 million, up 2.82% over the prior year.
  • Non-Current Debt was $34.8 million for Q4 2025 at Apyx Medical, up from $34.6 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $34.8 million in Q4 2025 and bottomed at $9.0 million in Q3 2023.
  • Average Non-Current Debt over 3 years is $31.5 million, with a median of $33.9 million recorded in 2024.
  • Peak annual rise in Non-Current Debt hit 275.77% in 2024, while the deepest fall reached 2.13% in 2024.
  • Year by year, Non-Current Debt stood at $33.2 million in 2023, then grew by 2.13% to $33.9 million in 2024, then grew by 2.82% to $34.8 million in 2025.
  • Business Quant data shows Non-Current Debt for APYX at $34.8 million in Q4 2025, $34.6 million in Q3 2025, and $34.4 million in Q2 2025.